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Pain Abbreviations used in this paper: ANOVA, analysis of variance; GI,
gastrointestinal; GSRS-IBS, Gastrointestinal Symptom Rating Scale-IBS;
HAD, Hospital Anxiety andDepression scale; IBS, irritable bowel syndrome;
IBSQOL, Irritable Bowel Syndrome Quality of Life Questionnaire; IBS-SSS,
IBS severity scoring system; PHQ-15, Patient Health Questionnaire-15;
PRO, patient-reported outcome; VAS, visual analogue scale.BACKGROUND & AIMS: Little is known about the link between
pathophysiologic factors and symptoms of irritable bowel
syndrome (IBS), or whether these factors have cumulative ef-
fects on patient-reported outcomes (PROs). We investigated
whether pathophysiologic alterations associated with IBS have
cumulative or independent effects on PROs. METHODS: We
performed a retrospective analysis of data from 3 cohorts of
patients with IBS (n ¼ 407; 74% female; mean age, 36 ± 12
years), based on Rome II or Rome III criteria, seen at a
specialized unit for functional gastrointestinal disorders in
Sweden from 2002 through 2014. All patients underwent as-
sessments of colonic transit time (radiopaque markers);
compliance, allodynia, and hyperalgesia (rectal barostat);
anxiety and depression (Hospital Anxiety and Depression
scale), as pathophysiologic factors. Dysfunction was defined by
available normal values. PROs included IBS symptom severity,
somatic symptom severity, and disease-specific quality of life.
RESULTS: Allodynia was observed in 36% of patients,
hyperalgesia in 22%, accelerated colonic transit in 18%,
delayed transit in 7%, anxiety in 52%, and depression in 24%:
each of these factors was associated with severity of at least 1
symptom of IBS. Rectal compliance was not associated with
more severe symptoms of IBS. At least 3 pathophysiologic
factors were present in 20% of patients, 2 in 30%, 1 in 31%,
and none in 18%. With increasing number of pathophysiologic
abnormalities, there was a gradual increase in IBS symptomseverity (P < .0001) and somatic symptom severity (P <
.0001), and a gradual reduction in quality of life (P < .0001).
CONCLUSION: Visceral hypersensitivity, including allodynia
and hyperalgesia, abnormal colonic transit, and psychologic
factors are all associated with IBS symptoms. These factors
have a cumulative effect on gastrointestinal and non-
gastrointestinal symptoms, as well as on quality of life, in
patients with IBS and are therefore relevant treatment
targets.Keywords: Visceral Hypersensitivity; Colonic Transit; Psycho-
logic Distress; Patient-Reported Outcomes.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Little is known about the link between pathophysiologic
factors and symptoms of irritable bowel syndrome (IBS),
or whether these factors have cumulative effects on
patient-reported outcomes.
NEW FINDINGS
Visceral hypersensitivity, including allodynia and
hyperalgesia, abnormal colonic transit, and psychologic
factors are all associated with IBS symptoms, and have
a cumulative effect on symptoms and QOL in IBS.
LIMITATIONS
Some important pathophysiologic factors in IBS, eg,
factors in the gut microenvironment, were not
investigated in this study.
IMPACT
The cumulative effect of visceral hypersensitivity,
abnormal colonic transit, and psychologic factors on
patient-reported outcomes in IBS highlight the
importance of gut-brain interactions, and indicate that
these pathophysiologic factors constitute relevant
treatment targets.rritable bowel syndrome (IBS) is a common functionalIgastrointestinal (GI) disorder, characterized by
abdominal pain associated with abnormal bowel habit, but
patients also often suffer from other GI and non-GI symp-
toms, including psychologic symptoms and psychiatric
comorbidity.1The efficacy of available therapeutic options
for this large group of patients is limited, which partly re-
lates to the fact that mechanisms underlying symptom
generation are incompletely known.2,3 The pathophysiology
of IBS is considered to be complex and most likely
multifactorial, and abnormal gut-brain interactions are
considered to be of great importance.4 Of the individual
pathophysiologic factors, visceral hypersensitivity,5–8
abnormal GI motor function,5,6,9 and abnormal brain func-
tion with abnormal central processing of visceral afferent
signals, which may be driven by psychologic symptoms
modulating the processing and perception of these sig-
nals,10–12 have all been widely studied and are believed to be
of importance for symptoms in subsets of patients with IBS.
Factors in the gut microenvironment are increasingly being
recognized as belonging in the pathophysiologic model of
IBS as well.4,13–17 However, the relevance of these factors for
symptom generation and severity in IBS is largely unknown.
Visceral hypersensitivity is one of the best characterized
pathophysiologic abnormalities in IBS. It consists of 2
components: allodynia, which means that an innocuous
stimulus is perceived as painful, and hyperalgesia, which
means an enhanced pain response (ie, a painful stimulus is
felt more intensely).18 In IBS, most studies have focused on
a lowered pain threshold as a marker of visceral hyper-
sensitivity, which reflects allodynia.6–8,19,20 However,
increased perceived intensity of a painful stimulus (ie,
hyperalgesia) also has been reported.5,7 Several studieshave demonstrated an association between presence of
visceral hypersensitivity, mostly defined as lowered rectal
or colonic pain thresholds, and IBS symptom severity,6,7,21
and this can be observed even after controlling for psy-
chologic symptoms and general symptom reporting.22 There
are also studies that have demonstrated an association be-
tween intensity ratings (visual analogue scales, VAS) during
painful rectal balloon distensions, reflecting hyperalgesia,
and IBS symptom severity.7 Moreover, in studies assessing
colorectal sensitivity, in which compliance is frequently
measured as well, reduced rectal compliance has been re-
ported in patients with IBS in some studies, but the asso-
ciation of this with IBS symptom severity is also less well
established.20,21
Abnormal GI motor function is another hallmark path-
ophysiologic factor in IBS, although a specific motor pattern
for IBS has not been identified and clear correlations be-
tween motility findings and symptoms have been difficult to
demonstrate.23,24 However, measurement of colonic or
oroanal transit time as an indirect measure of colonic
motility shows more consistent findings, with colonic transit
abnormalities being associated with IBS subtype in that
accelerated transit is seen predominantly in patients with
diarrhea, and delayed transit in patients with con-
stipation.5,9,25–27 Moreover, even though it has been hard to
associate specific motility abnormalities in IBS with pain
severity,5 some studies have found transit to be weakly but
significantly associated with pain and/or bloating, in addi-
tion to the association with bowel habit abnormalities.9,27
Psychologic symptoms, such as anxiety and depressive
symptoms, in more severe cases fulfilling the criteria for
comorbid anxiety or depressive disorders, are common in
patients with IBS,28 and the presence of comorbid anxiety
and depressive symptoms or syndromes is associated with
the overall GI symptomatology.29 In the latest edition of the
diagnostic criteria for functional GI disorders, the Rome IV
criteria, these disorders are referred to as disorders of gut-
brain interaction, highlighting the importance of not only
the gut but also the brain in symptom generation in these
conditions.30 Indeed, altered central nervous system or
brain function has been demonstrated in patients with IBS
compared with control subjects using brain imaging.11
However, in one study the group brain differences be-
tween IBS and healthy controls disappeared when control-
ling for anxiety and depression,31 which indirectly suggests
that measures of anxiety and depression can be used as
proxy measures for abnormal brain function in patients
with IBS, although abnormal brain dysfunction in IBS may
indeed exist irrespective of anxiety and depression accord-
ing to other studies.32
Few studies have investigated how the different patho-
physiologic factors in IBS relate to each other and how they
interact to influence symptoms, that is, whether they are
individually independent pathophysiologic factors or
whether they are correlated in their presence and impact on
symptoms. Visceral hypersensitivity is associated with
psychologic factors, but its association with GI symptoms is
not solely explained by psychologic factors.7,22,33 The asso-
ciation between visceral hypersensitivity and GI motility has
been assessed in a small number of trials with inconsistent 
results and with no attempts to assess their combined in-
fluence on symptoms.6,20 The association between GI 
motility and psychologic factors such as stress, anxiety and 
depression has been established with different methodolo-
gies,34,35 but their combined influence on symptoms has not 
been evaluated. In line with the current view on functional 
GI disorders as disorders of gut-brain interaction,30 it seems 
reasonable to hypothesize that different factors involved in 
the complex pathophysiology of IBS may interact and in-
fluence symptoms in a cumulative fashion in these patients, 
but evidence from studies supporting this is not available. 
However, it also may be possible that these factors do not 
act cumulatively but instead influence symptoms in an in-
dependent way, which was suggested for colorectal motility 
and visceral hypersensitivity in one study.6
Therefore, the aim of the present study was to evaluate 
whether key pathophysiologic factors have a cumulative 
effect on symptoms and disease-specific quality of life in 
IBS. Specifically we aimed to determine the presence of 
visceral hypersensitivity as reflected by allodynia and 
hyperalgesia, abnormal rectal compliance, delayed or 
accelerated colonic transit, reflecting abnormal colonic 
motility, and anxiety and depression symptoms, reflecting 
abnormal brain function, and to evaluate how the presence 
of one or more of these influence relevant patient-reported 
outcomes (PROs) in IBS, that is, IBS and overall somatic 
symptom severity, and IBS-specific quality of life.
Materials and methods
Subjects
We included subjects with IBS aged 18 to 70 years from 3 
prospective cohort studies that were conducted to assess the 
relevance of different pathophysiologic factors for IBS symp-
toms. For this study, we included only subjects who had 
completed measurements of rectal sensitivity and compliance, 
colonic (eg, oroanal) transit time, anxiety and depression, 
severity of GI and overall somatic symptoms and disease-
specific quality of life (see later in this article for details; in-
vestigations and questionnaires completed within a 2-week 
period). The patients in the first cohort were included be-
tween 2002 and 2007, patients in the second cohort between 
2007 and 2010, and patients in the third cohort between 2010 
and 2014. The patients were included at a specialized unit for 
functional GI disorders at the University of Gothenburg, Swe-
den, and predominantly referred to the unit from primary care, 
but self-referral was also accepted. All patients were seen by a 
gastroenterologist (HT or MS) who confirmed the diagnosis 
based on a typical clinical presentation and additional tests if 
needed. However, most patients had already undergone suffi-
cient examinations before referral. All patients fulfilled the 
current diagnostic criteria at the time of inclusion, that is, the 
Rome II criteria up to 2006,36 and the Rome III criteria there-
after.37 The patients were subtyped according to predominant 
bowel habit based on the Rome II or III recommendations,36,37 
and defined as diarrhea-predominant or constipation-
predominant IBS, whereas patients with IBS with mixed/
alternating type and unsubtyped IBS were combined into 1 
group for the analyses in this study (ie, nonconstipation- ordiarrhea-predominant IBS; nonC or nonD). Exclusion criteria
were as follows: other GI disease(s) explaining the patient’s
symptoms; other severe disease(s) such as malignancy, severe
heart disease, kidney disease, or neurological disease; symp-
toms indicating other severe disease(s) such as GI bleeding,
weight loss not explained by altered eating habits; fever; severe
psychiatric disease being the dominant clinical problem; a
history of drug or alcohol abuse within 6 months before
enrollment; or pregnancy at the time of the study. All subjects
refrained from the use of drugs affecting GI function at least 48
hours before the investigations. The studies were approved by
the Regional Ethical Review Board in Gothenburg, and all pa-
tients gave verbal and written informed consent before any
study-related procedures were undertaken.
Pathophysiologic Measures
In all studies, a rectal barostat test, a measure of colonic
transit (eg, oroanal transit time), and a questionnaire to assess
anxiety and depressive symptom severity were included.
However, the protocols used differed slightly between study
cohorts (see later in this article). Other measures of potential
relevance for IBS pathophysiology were included in the study
protocols as well, but these were not consistent between the
study protocols, have been reported elsewhere,16,17,38–45 and
were not included in the analyses presented here. A proportion
of the subjects have been included in previous publications
focusing on the individual abnormalities assessed in this
study,9,20,22 but not including the specific analyses performed
in this study.
Oroanal transit time. The subjects ingested 10 radi-
opaque markers every morning for 5 days. On the sixth day
they ingested 5 radiopaque markers in the morning and 5 at 8
PM. On the seventh day, the subject came to the laboratory at 8
AM and the remaining radiopaque markers were counted using
fluoroscopy (Exposcop 7000 Compact; Ziehm GmbH, Nürem-
berg, Germany). Oroanal transit time (days) was calculated by
dividing the number of remaining radiopaque markers by 10
(ie, the daily dose of radiopaque markers). To define acceler-
ated and delayed oroanal transit time we used normal values
(5th and 95th percentile) obtained from investigations in 199
healthy volunteers at our laboratory (women 0.9–3.9 days; men
0.7–2.1 days).9,27,46–48
Rectal barostat. Two different rectal barostat protocols
were used to study rectal sensitivity and compliance. In the
first and second cohorts we used a protocol with phasic
isobaric distensions lasting 30 seconds followed by a 30-second
interval at the individual operating pressure.7,20 Distensions
were performed with stepwise increments starting at the in-
dividual operating pressure and increasing 5 mm Hg until the
subject reported pain or when a pressure of 70 mm Hg was
reached. At the end of this protocol (ie, at the pain threshold),
the intensity of pain was rated by the patients using VAS. For
this study, the pain threshold (mm Hg) was used as a measure
of allodynia, and the VAS pain intensity rating at the pain
threshold was used as a measure of hyperalgesia. The first 5
distension steps of the pressure-volume curves were used for
analysis of compliance, as the initial part of the curve is linear,
which enables quantification of dynamic compliance as the
linear slope of the curve. Furthermore, data up to the fifth
distension step were available in most subjects, because most
subjects had not yet reached the pain threshold at this step.20
Anxiety and depression. The presence of anxiety and/
or depressive symptoms was used as a proxy measure for
abnormal central nervous system or brain function, hence
abnormal central processing of visceral afferent signals, in this
study. All patients completed the widely used and thoroughly
validated Hospital Anxiety and Depression scale (HAD), and the
validated cutoff score of >7 on either the anxiety or depression
subscales was used to define abnormality.50,51
To identify patients with allodynia, hyperalgesia, and 
increased/decreased compliance, respectively, we used normal 
values (5th and 95th percentile) obtained from investigations 
in 35 healthy volunteers at our laboratory (pain threshold <31 
mm Hg; pain intensity at pain threshold >54 mm; compliance 
2.9–10.4 mL/mm Hg).7,20,22 In the third cohort, allodynia (pain 
threshold) and compliance were measured by using ramp in-
flations starting from 0 mm Hg with 4 mm Hg increments every 
minute until the subject reported pain.22,49 The balloon pres-
sure at half the maximum observed volume was used as a 
summary value for compliance, whereby a smaller pressure 
corresponds to higher compliance.49 After the ramp inflations,
60-second phasic distensions of 12, 24, 36, and 48 mm Hg 
above the operating pressure were each applied once in 
random order. The subjects rated the intensity of sensations of 
gas, urgency, discomfort, and pain at each of these distensions. 
For the purpose of this study, the pain threshold (mm Hg) was 
used as a measure of allodynia, and pain ratings at the 24 mm 
Hg distension were used as measure of hyperalgesia, because 
this was in the painful range for most subjects. To identify 
patients with allodynia, hyperalgesia, and increased/decreased 
compliance, respectively, we used normal values (5th and 95th 
percentile) obtained from investigations in 50 healthy volun-
teers at our laboratory (pain threshold <20 mm Hg; pain in-
tensity at 24 mm Hg phasic distension >76 mm; compliance 
(pressure at half maximal volume): 12–27 mm Hg).22PRO Instruments
In all 3 cohorts, the patients completed questionnaires to
assess IBS symptom severity, overall somatic symptom severity,
and disease-specific quality of life. However, the questionnaires
used differed between the cohorts (see later in this article).
IBS symptoms. In the first cohort, the Gastrointestinal
Symptom Rating Scale-IBS (GSRS-IBS) was used to determine
IBS symptom severity. GSRS-IBS consists of 13 questions, sum-
marized in 5 domains (abdominal pain, bloating, constipation,
diarrhea, and satiety).52 In the second and the third cohort, IBS
symptom severity was determined using the IBS severity
scoring system (IBS-SSS), and this questionnaire is based on 5
items: severity and frequency of abdominal pain, severity of
abdominal distension, dissatisfaction with bowel habits, and
interference of IBS with daily life.53 The patients also completed
a stool diary for 1 week using the Bristol Stool Form scale54;
from these diaries, information about average stool frequency
and average stool consistency over a week was obtained.
Overall somatic symptoms. We used 2 different
measures of overall somatic symptom severity, often referred
to as somatization. Patients in the first cohort completed the
Symptom Checklist-90, a questionnaire developed to measure
psychological symptom patterns of psychiatric and medical
patients.55 It consists of 9 primary symptom dimensions, but
for this study we used only the somatization subscale. In the
second and third cohorts, the Patient Health Questionnaire-15(PHQ-15) was used. PHQ-15 assesses the perceived severity
of 15 different somatic symptoms, which are summarized into
an overall somatic symptom severity score.56
Disease-specific quality of life. IBS-specific quality of
life was measured in all 3 patient cohorts with the Irritable
Bowel Syndrome Quality of Life Questionnaire (IBSQOL).57 This
30-item questionnaire measures 9 quality of life domains found
to be of relevance for IBS: emotional health, mental health,
sleep, energy, physical functioning, food/diet, social func-
tioning, physical role, and sexual relations. Each scale score is
transformed to a scale of 0 to 100, with 100 representing the
best possible quality of life.
Data Analysis and Statistics
The first step in the data analysis was to identify patients
with IBS with pathophysiologic abnormalities. Patients with
results from the barostat and transit tests used in this study
that were outside the 5th and/or 95th percentile in healthy
control subjects, as appropriate, were defined as having rectal
allodynia, rectal hyperalgesia, increased/decreased rectal
compliance, or accelerated/delayed transit, respectively, and
validated cutoff values for the HAD questionnaire were used to
identify patients with anxiety and depression (see previ-
ously).50,51 To be included in the next step of the analyses, a
pathophysiologic factor had to be associated with the severity
of 1 IBS-related symptom (IBS-SSS pain frequency and
severity, bloating severity, dissatisfaction with bowel habits;
GSRS-IBS abdominal pain, bloating, constipation, diarrhea;
average stool frequency and consistency from Bristol Stool
Form stool diaries), and in the expected direction, that is, more
severe symptoms in patients with the pathophysiologic factors
than in those without. This was tested with independent sam-
ples t tests between subjects with and without the patho-
physiologic abnormality. For the identification of relevant
pathophysiologic factors to be included in the next step in the
analyses, we used uncorrected P values <.05 as the cutoff, but
we also performed false discovery rate correction for multiple
testing to indicate P values that survived false discovery rate
correction. The number of pathophysiologic abnormalities in
each patient was thereafter defined. To test the hypothesis that
the pathophysiologic abnormalities have a cumulative effect on
PROs, 1-way between-groups analysis of variance (ANOVA)
with linear trend analyses to analyze the presence of a linear
trend were performed,58 with number of pathophysiologic ab-
normalities as independent variable and the patient-reported
outcome variable (IBS symptom severity, overall somatic
symptom severity or IBS-specific quality of life) as the depen-
dent variable. Effect size was evaluated using the following
definition: small: partial eta squared 0.01; medium: partial eta
squared 0.06; large: partial eta squared 0.14.59 To be able to
use single measures for IBS and overall somatic symptom
severity for these analyses across all 3 patient cohorts, scores
from the questionnaires measuring these variables in the
studies (IBS-SSS and GSRS-IBS; Symptom Checklist-90 somati-
zation subscale, and PHQ-15)52,53,55,56 were transformed to z
scores (defining how many standard deviations a value is from
the mean, which is set to 0), and those z scores were thereafter
used as the IBS and somatic symptom severity variables for all
patients. In addition to analyses performed in the entire cohort,
we repeated the linear trend analyses in the 3 individual IBS
cohorts to assess congruence of findings across the cohorts.








(n ¼ 142) Pa
Age, yr, mean ± SD (range) 36.0 ± 12.0 (19–67) 36.8 ± 12.2 (19–67) 36.8 ± 12.2 (19–67) 34.4 ± 11.5 (19–67) .17
Gender (female/male) 301/106 101/36 101/27 99/43 .23
IBS subtype (C/D/nonCnonD) 99/145/163 25/47/65 35/41/49 39/54/49 .18
HAD anxiety 8.1 ± 4.6 7.9 ± 4.7 8.1 ± 4.5 8.3 ± 4.5 .81
HAD depression 5.2 ± 3.7 5.1 ± 3.6 5.3 ± 3.9 5.1 ± 3.5 .86
Z score somatic symptom severity 0.0 ± 1.0 0.0 ± 1.0 0.1 ± 1.0 0.1 ± 1.0 .19
Z score IBS symptom severity 0.0 ± 1.0 -0.2 ± 1.0 0.0 ± 1.0 0.0 ± 1.0 .21
Oroanal transit time, d 1.6 ± 1.0 1.7 ± 1.1 1.7 ± 1.0 1.5 ± 1.1 .38
Rectal pain threshold, mm Hg (protocol 1) NA 34 ± 13 31 ± 13 NA .02
Rectal pain intensity, mm
(at pain threshold; protocol 1)
NA 33 ± 23 34 ± 25 NA .69
Rectal pain threshold, mm Hg (protocol 2) NA NA NA 27 ± 8 NA
Rectal pain intensity, mm
(at 24 mm Hg; protocol 1)
NA NA NA 48 ± 33 NA
IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS; IBSnonCnonD, nonconstipation or diarrhea-
predominant IBS, hence patients with IBS mixed/alternating type and unsubtyped IBS; SD, standard deviation.
aANOVA or c2 test among the 3 different cohorts.We also used an alternative grouping of pathophysiologic
abnormalities, whereby we identified patients with psychologic
distress (anxiety and/or depression using the same cutoff
values as described previously), hypersensitivity (allodyniaFigure 1. (A) Proportion of
subjects with pathophysi-
ologic abnormalities rele-
vant for IBS symptoms






depression), and (B) pro-
portion of subjects with
different numbers of path-
ophysiologic abnormalities





depression.and/or hyperalgesia, defined as described previously) and
abnormal transit (delayed or accelerated, as described previ-
ously). The same analytical approach as described previously
regarding association between the number of these
pathophysiologic factors and patient-reported outcome vari-
ables were also used for these factors. In addition, we per-
formed multivariate linear regression models with presence of 
abnormal transit, hypersensitivity, and psychologic distress as 
dichotomous independent variables in 2 models, one with IBS 
symptom severity and another with overall somatic symptom 
severity as the dependent variable. In general a P-value <.05 
was considered statistically significant, and data are presented 
as mean ± standard deviation and proportions as appropriate.Results
Subjects
We included 407 subjects with IBS; 137 in cohort 1 
diagnosed according to the Rome II criteria, and 128 and 
142 in cohorts 2 and 3, respectively, both diagnosed ac-
cording to the Rome III criteria. Demographic and disease-
related information can be seen in Table 1. There were no 
differences in mean age, gender distribution, or distribution 
of IBS subtypes among the 3 cohorts. Moreover, except for a 
slightly lower rectal pain threshold in cohort 2 than in 
cohort 1, all the parameters used in the main analyses in 
this study were equivalent across the cohorts, that is, 
oroanal transit time, overall IBS symptom severity z scores, 
somatic symptom severity z scores, and anxiety and 
depression scores (HAD). The rectal pain threshold in 
cohort 3 was numerically lower, and the rectal pain in-
tensity numerically higher than in cohorts 1 and 2, but this 
was expected, because a different barostat protocol with 
different normal values was used in this cohort. Therefore, 
the 3 cohorts are combined in all analyses in this report. 
Oroanal transit time differed between IBS subtypes 
(ANOVA, P < .0001; post hoc comparisons, Bonferroni 
adjusted, P < .05 between all groups), and patients with 
IBSnonCnonD had lower HAD depression scores (ANOVA, 
P ¼ .02; post hoc comparisons, Bonferroni adjusted, P < .05between IBSnonCnonD and constipation-predominant IBS
only), but otherwise the pathophysiologic measures and
PROs were similar among IBS subtypes (Supplementary
Table 1)Pathophysiologic Factors
Based on normal values and validated cutoff scores,
allodynia was found in 145 patients (36%), hyperalgesia in
86 patients (22%), accelerated oroanal transit in 73 patients
(18%), delayed oroanal transit in 29 patients (7%), anxiety
in 211 patients (52%), and depression in 97 patients (24%)
(Figure 1A). All of these factors were associated with the
severity of at least 1 IBS symptom, that is, more severe
symptoms in patients with vs without the pathophysiologic
factor (Table 2). Anxiety and depression were associated
with the largest number of IBS symptoms, transit abnor-
malities primarily with bowel habit disturbances, and allo-
dynia and hyperalgesia with pain and bowel habits. Rectal
compliance, which was increased in 58 patients (14%) and
reduced in 38 patients (9%) was not associated with more
severe IBS symptoms, and therefore not included in the
subsequent analyses. At least 3 pathophysiologic abnor-
malities relevant for symptoms were present in 82 patients
(20.1%), 2 abnormalities in 121 patients (29.7%), 1 ab-
normality in 28 patients (31.4%), and 76 patients (18.7%)
had none of the abnormalities under consideration
(Figure 1B). There were no associations between the num-
ber of pathophysiologic abnormalities and sex (P ¼ .12), age
(P ¼ .15), or IBS subtype (P ¼ .21).
Psychologic distress (anxiety and/or depression) was
seen in 227 patients (56%), hypersensitivity (allodynia and/
or hyperalgesia) in 190 patients (47%), and abnormal
transit (accelerated or delayed) in 102 patients (25%); all 3
of these abnormalities were present in 19 patients (4.7%), 2
in 150 patients (36.9%), 1 in 162 patients (39.8%), and 76Figure 2. Venn diagram
demonstrating the overlap
between pathophysiologic
factors in our IBS cohort









six of the patients (18.7%)
had none of the abnor-
malities; these patients are
not included in the figure.
The size of the different
areas are not entirely pro-
portional to the number of
subjects in each area.
Table 2. IBS Symptom Severity in Patients With Vs Without Pathophysiological Factors





































































































































































































































































NOTE. Comparisons between patients with and without the pathophysiologic factor. Comparisons for IBS-SSS are done in cohorts 2 and 3 (n ¼ 270), GSRS-IBS in cohort
1 (n ¼ 137), and for stool diaries using Bristol Stool Form (BSF) Scale in the entire cohort (n ¼ 407). The number of patients with the individual pathophysiologic factors are
shown. Exact P values at the uncorrected level are displayed and significant differences (P < .05) at the uncorrected level are shown in bold. The P values that survive FDR
(false discovery rate) correction for multiple testing are indicated with # (all but 5 survive FDR correction). Comparisons displaying an inverse correlation, that is, more
severe symptoms in patients without the pathophysiologic factor present, are displayed within parentheses.
patients (18.7%) had none of the abnormalities. The overlap 
between these variables can be seen in Figure 2.Association Between Number of 
Pathophysiologic Factors and PROs
For analysis purposes, the patients were placed in 4 
groups based on the number of pathophysiologic abnor-
malities relevant for IBS symptom severity; none, 1, 2, or 3 
or more abnormalities. Symptom severity showed a gradual 
increase with increasing number of pathophysiologic fac-
tors, with medium effect size for IBS symptom severity 
(Partial ƞ2 ¼ 0.093; P < .0001) and large effect size for 
overall somatic symptom severity (Partial ƞ2 ¼ 0.159; P < 
.0001) (Figure 3A; Table 3). There was a gradual decrease in 
quality of life with increasing number of pathophysiologic 
factors with medium to large effect sizes for all IBSQOL 
domains except for the food domain (small effect size)
(Figure 3B, Table 3). Separate analyses in the 3 IBS cohorts 
yielded similar results with medium to large effect sizes for 
IBS and overall somatic symptom severity, as well as for 
most of the IBSQOL domains; significant linear trends were 
seen for all the analyses except for 2 IBSQOL domains in IBScohort 2 and 1 in IBS cohort 3 (Supplementary Figure 1,
Supplementary Table 2).
In a subsequent step we performed the same analyses
but removed anxiety and depression, that is, used only 3
pathophysiologic factors (allodynia, hyperalgesia, and
abnormal oroanal transit), and placed individuals into 3
groups (none, 1, or 2 or more abnormalities). For all the
PROs except for the IBSQOL emotional subscale, significant
linear trends with gradually increasing symptom severity
and decreasing IBS-specific quality of life with increasing
number of pathophysiologic abnormalities were seen, but
the effect sizes were reduced to small (Table 3). When only
anxiety and depression were used in the analyses (no, 1, or
2 abnormalities), significant linear trends with gradually
increasing symptom severity and decreasing IBS-specific
quality of life with increasing number of pathophysiologic
abnormalities with medium to large effect sizes were seen
(Table 3).
Using the alternative grouping of pathophysiologic fac-
tors (psychologic distress, hypersensitivity, and abnormal
transit) yielded similar results with significant linear trends,
but a tendency toward smaller effect sizes compared with
the model with a larger number of pathophysiologic factorsFigure 3.Gradual increase
in (A) IBS symptom
severity (z score of IBS-
SSS and GSRS-IBS total
scores) and overall so-
matic symptom severity (z
score of PHQ-15 and
Symptom Checklist-90
somatization subscale),
and (B) gradual decrease
in IBSQOL for all domains
with increasing number of
pathophysiologic abnor-
malities. P values from
ANOVA with linear trend
analysis.
Table 3.ANOVA With Linear Trend Analyses: Number of Pathophysiologic Factors and Patient-Reported Outcomes
All factors
Allodyniaþhyperalgesia
þtransit Anxiety & depression
Partial ƞ2 P Partial ƞ2 P Partial ƞ2 P
IBS sx .093b .000 .021a .004 .107b .000
Somatic sx .159c .000 .022a .003 .197c .000
IBSQOL_Emotional .138b .000 .004 .223 .231c .000
IBSQOL_Mental .219c .000 .012a .041 .356c .000
IBSQOL_Sleep .108b .000 .051a .000 .100b .000
IBSQOL_Energy .167c .000 .042a .000 .172c .000
IBSQOL_PhysFunct .075b .000 .030a .001 .092b .000
IBSQOL_Food .045a .000 .015a .018 .045a .000
IBSQOL_SocialRole .093b .000 .014a .021 .126b .000
IBSQOL_PhysicalRole .074b .000 .012a .032 .098b .000
IBSQOL_Sexual .075b .000 .034a .002 .077b .000
NOTE. Significance indicated in bold.




(Table 4). Furthermore, multivariate linear regression
models with IBS symptom severity and overall somatic
symptom severity as dependent variables, and psychologic
distress, hypersensitivity, and abnormal transit as dichoto-
mous independent variables, demonstrated that hypersen-
sitivity and psychologic distress were both independently
associated with the outcome variables (Supplementary
Tables 3 and 4).Table 4.ANOVA With Linear Trend Analyses: Number of
Pathophysiologic Factors Using the Alternative
Grouping, Psychologic Distress, Hypersensitivity
and Abnormal Transit, and Patient-Reported
Outcomes
Psychologic distress,
hypersensitivity þ abnormal transit
Partial ƞ2 p-value
IBS sx .066b .000














In this study, we have demonstrated in a large group of
patients with IBS that well-defined pathophysiologic factors
that are putatively involved in symptom generation in pa-
tients with IBS seem to influence relevant patient-reported
outcome variables in a cumulative fashion. Specifically,
visceral hypersensitivity, that is, allodynia and hyperalgesia,
abnormal oroanal or colonic transit, and psychologic factors
were all associated with GI symptom severity in IBS, and
demonstrated a cumulative effect on the severity of GI and
non-GI symptoms, as well as on quality of life impairment in
IBS. Our findings fit well with the current view on the
important role of gut-brain interactions (ie, reciprocal
communication between the gut and the brain) in symptoms
in patients with functional GI disorders such as IBS.1,30
All of the pathophysiologic factors we included in this
study have been shown in previous studies to be associated
with, and hence of potential relevance for, severity of
symptoms in patients with IBS.5–7,9,21,22,25–27,29 Regarding
the association with IBS symptoms, previous studies have
indicated that colonic motility (mostly measured as colonic
or oroanal transit time) is more clearly associated with the
abnormal bowel habits in IBS,5,9,25–27 whereas visceral hy-
persensitivity seems to be more clearly associated with
abdominal pain.6,7 Only psychologic distress and visceral
hypersensitivity have demonstrated an association with
overall IBS symptom severity.7,21,22,29 Our analyses confirmthese findings with a general pattern of association between
motility/transit and bowel habit abnormalities, visceral
hypersensitivity and abdominal pain, and psychologic
factors being of importance for the overall IBS symptom-
atology. However, our study extends beyond the previous
studies, as it also demonstrates a striking cumulative effect
of these factors on the overall IBS symptomatology, and also
on overall somatic symptom severity and disease-specific
quality of life, highlighting the importance of considering
and assessing combinations of pathophysiologic factors in
IBS and pointing toward the importance of the gut-brain
axis in this process.30 Our findings also seem robust, as 
different approaches to grouping the pathophysiologic fac-
tors yielded similar results, and the findings in the overall 
IBS cohort were congruent with findings in the 3 individual 
IBS cohorts analyzed separately. Moreover, even though 
anxiety and depression were the strongest factors when it 
comes to the overall symptomatology in our IBS sample, 
removing these factors from the analyses did not eliminate 
the significant linear trend between the number of patho-
physiologic factors and the severity of PROs, although the 
effect sizes were reduced. However, even though our study 
indicates that abnormal transit seems to contribute the least 
of the pathophysiologic factors to the PROs, it is of impor-
tance because it contributed significantly to several of the 
models tested. This indicates that the cumulative effect seen 
is not solely explained by the psycholologic factors included 
in our study.
Current therapeutic options in IBS have limited efficacy. 
Positive effects on symptoms are achieved in only subsets of 
patients, and in most patients the available therapies only 
produce partial improvement in symptoms and rarely lead 
to complete symptom resolution.2,3 This fits well with the 
findings in this study, in which many patients demonstrated 
the presence of several pathophysiologic abnormalities, 
with a complex overlap pattern, and greater number of 
these abnormalities associated stepwise with greater 
symptom severity. Hence, targeting only one of these key 
pathophysiologic factors is unlikely to lead to complete 
symptom resolution, even if that abnormality is present in 
the individual patient. Based on our findings, it is tempting 
to speculate that combining therapies that target different 
levels of the gut-brain axis and different pathophysiologic 
factors simultaneously might lead to improved treatment 
outcomes. However, that hypothesis of course needs to be 
tested in prospective treatment trials. Furthermore, in to-
day’s clinical setting, the symptom profile is used to guide 
therapy,2 and knowledge about the pathophysiology in the 
individual patients is rarely available, which probably 
further reduces the likelihood of treatment success. In the 
future, more personalized treatment approaches based on 
the underlying pathophysiology, including combinations of 
abnormalities, may optimize the treatment approach to 
these subtypes of patients with IBS defined on more com-
plex merits than bowel habits and dominant symptoms.2
Our study had several strengths. We studied a well-
characterized and large group of patients with IBS evalu-
ated at an expert center for functional GI disorders and used 
the current state of the art methodology for assessment of 
pathophysiology in IBS. Moreover all patients were studied 
in a single center using uniform study methodology and 
design, except for use of different questionnaires and rectal 
barostat protocols during different time periods. However, 
the slight differences in the methodology across the cohorts 
were of minor importance because the main findings in the 
overall cohort were also seen in the 3 individual IBS cohorts. 
Moreover, being evaluated at an expert center can be 
considered as a weakness as well, because the findings 
might not be generalizable to patients with IBS in the 
community. We believe that this a minor issue in this cohortbecause almost all patients were referred from primary care
or through self-referral specifically for general advice
regarding treatment and investigations, but were otherwise
managed in primary care, just as community patients with
IBS. The update of diagnostic criteria for IBS over the course
of this study (ie, Rome II to Rome III)36,37 also could be
viewed as a weakness, but because the 3 cohorts were
similar regarding demographic factors as well as GI, overall
somatic, and psychologic symptom severity, we consider it
unlikely that this had any relevant impact on our findings.
Moreover, we focused on a limited number of pathophysi-
ology factors, and there are of course other factors of po-
tential relevance in IBS that were not included in this study,
such as variations in the gut microenvironment.13–17 We
also used psychologic symptoms as a proxy measure for
abnormal brain function, which may not be entirely accu-
rate, but for the purpose of the analyses in this study we
consider this approach to be acceptable.
In conclusion, we have demonstrated in this study that
visceral hypersensitivity, that is, allodynia and hyperalgesia,
abnormal colonic or oroanal transit, and psychologic factors,
are all associated with GI symptom severity in IBS. These
factors seem to have a cumulative effect on GI and overall
somatic symptoms, as well as on quality of life in IBS, and
therefore constitute relevant treatment targets. Future
studies should assess whether other pathophysiologic fac-
tors, such as abnormal gut microenvironment, can add to
this model and explain even more of the variance in the
symptomatology in patients with IBS and interact with the
pathophysiologic factors investigated in this study. More-
over, treatment studies targeting multiple pathophysiologic
factors simultaneously in patients with IBS with combina-
tions of these abnormalities should be performed to assess
if this approach leads to greater therapeutic impact on
symptoms than current treatment approaches targeting
predominant symptoms without specific knowledge about
the underlying pathophysiology in the individual patient.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
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Supplementary Figures
1.Gradual increase in IBS
symptom severity (z score of
IBS-SSS and GSRS-IBS to-
tal scores) and overall so-
matic symptom severity (z
score of PHQ-15 and
Symptom Checklist-90 so-
matization subscale) with
increasing number of path-
ophysiologic abnormalities
in all IBS cohorts (A–C).
P values from ANOVA with
linear trend analysis.
Supplementary Table 1.Pathophysiologic Measures and Patient-Reported Outcomes Among IBS Subtypes
IBS-C (n ¼ 99) IBS-D (n ¼ 145) IBSnonCnonD (n ¼ 163) Pa
Age, y, mean ± SD 36.2 ± 11.3 36.9 ± 12.1 35.3 ± 12.4 .51
Gender, female/male 81/18 103/42 117/46 .14
HAD anxiety 8.8 ± 4.6 8.3 ± 4.8 7.6 ± 4.2 .08
HAD depression 5.7 ± 4.0 5.5 ± 3.8 4.6 ± 3.2 .02
Z score somatic symptom severity 0.1 ± 1.0 0.1 ± 1.0 -0.1 ± 1.0 .06
Z score IBS symptom severity 0.0 ± 0.9 0.0 ± 1.1 -0.2 ± 1.0 .34
Oroanal transit time, d 2.2 ± 1.3 1.2 ± 0.7 1.5 ± 0.9 .000
Rectal pain threshold, mm Hg (protocol 1) 32 ± 12 32 ± 13 33 ± 13 .82
Rectal pain intensity, mm (at pain threshold; protocol 1) 35 ± 22 35 ± 25 31 ± 22 .48
Rectal pain threshold, mm Hg (protocol 2) 27 ± 9 28 ± 9 27 ± 8 .90
Rectal pain intensity, mm (at 24 mm Hg; protocol 1) 55 ± 32 47 ± 32 44 ± 33 .29
IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS; IBSnonCnonD, nonconstipation or diarrhea-
predominant IBS, hence patients with IBS mixed/alternating type and unsubtyped IBS; SD, standard deviation.
aANOVA or c2 test among the 3 different cohorts.
Supplementary Table 2.ANOVA With Linear Trend Analyses: Number of Pathophysiologic Factors and Patient-Reported
Outcomes in the 3 IBS Cohorts
IBS cohort 1 (n ¼ 137) IBS cohort 2 (n ¼ 128) IBS cohort 3 (n ¼ 142)
Partial ƞ2 P Partial ƞ2 P Partial ƞ2 P
IBS sx .128b .000 .100b .000 .061b .003
Somatic sx .203c .000 .256c .000 .085b .000
IBSQOL_Emotional .174c .000 .173c .000 .090b .001
IBSQOL_Mental .226c .000 .319c .000 .149c .000
IBSQOL_Sleep .109b .000 .154c .000 .059a .000
IBSQOL_Energy .198c .000 .244c .000 .082b .001
IBSQOL_PhysFunct .119b .000 .018 .14 .103b .000
IBSQOL_Food .100b .000 .076b .002 .005 .41
IBSQOL_SocialRole .147c .000 .069b .003 .043a .019
IBSQOL_PhysicalRole .109b .000 .054a .010 .047a .014
IBSQOL_Sexual .064b .017 .043 .058 .147b .000
NOTE. Significance indicated in bold.




Supplementary Table 3.Linear Regression Analysis, IBS
Symptom Severity (z Score),
R2 ¼ 0.10
Estimate (B) SE b P
Constant 0.495 0.090 .000
Psychologic distress 0.512 0.098 0.250 .000
Hypersensitivity 0.325 0.098 0.160 .000
Abnormal transit 0.03 0.112 0.014 .773
NOTE. Factors independently associated with the outcome
variables indicated in bold.
Supplementary Table 4.Linear Regression Analysis, Overall
Somatic Symptom Severity
(z Score), R2 ¼ 0.17
Estimate (B) SE b P
Constant 0.549 0.086 .000
Psychologic distress 0.699 0.094 0.348 .000
Hypersensitivity 0.361 0.093 0.181 .000
Abnormal transit 0.040 0.107 0.017 .709
NOTE. Factors independently associated with the outcome
variables indicated in bold.
